Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gastrointestinal 1Dermatologic 1

Conditions

Sarcoma 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Colorectal Neoplasms 1

Interventions

pembrolizumab 22Nivolumab 17Magnetic Resonance Spectroscopy 12Specimen Handling 10Cyclophosphamide 9Radiosurgery 7Drug Therapy 6Radiotherapy 5Paclitaxel 5Ipilimumab 5fludarabine 4Biopsy 4trametinib 3sargramostim 3Trastuzumab 3Taxes 3Pemetrexed 3Metformin 3Interleukin-2 3Immunoglobulin G 3Gemcitabine 3Carboplatin 3Bevacizumab 3tremelimumab 2temsirolimus 2poly ICLC 2pertuzumab 2osimertinib 2motexafin gadolinium 2epacadostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × avapritinib × Dermatologic × Clear all
NCT04771520 2026-03-02

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

M.D. Anderson Cancer Center

Phase 2 Recruiting
50 enrolled
DermatologicGastrointestinalSarcomaThoracic

Lung Neoplasms, Melanoma, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡